Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05802186 · ClinicalTrials.gov registry record · NA
Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
A NA study of Lung Non-Small Cell Carcinoma and Lung Carcinoma, sponsored by Northwestern University.
- Recruiting
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT05802186: Recruiting NA study of Lung Non-Small Cell Carcinoma and Lung Carcinoma, sponsored by Northwestern University.
NCT05802186 is a NA study of Lung Non-Small Cell Carcinoma and Lung Carcinoma that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 70 participants, below the 159-participant average among 47 other Lung Non-Small Cell Carcinoma trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05802186, a NA study of Lung Non-Small Cell Carcinoma and Lung Carcinoma, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests the effectiveness and safety of artificial intelligence (AI) to determine dose recommendation during stereotactic body radiation therapy (SBRT) planning in patients with primary lung cancer or tumors that has spread from another primary site to the lung (metastatic). SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Even with the high precision of SBRT, disease persistence or reappearance (local recurrence) can still occur, which could be attributed to the radiation dose. AI has been used in other areas of healthcare to automate and improve various aspects of medical science. Because the relationship of dose and local recurrence indicates that dose prescriptions matter, decision support systems to help guide dose based on personalized prediction AI algorithms could better assist providers in prescribing the radiation dose of lung stereotactic body radiation therapy treatment.
Primary Outcome
LFS is defined as the length of time after SBRT that the patient survives without local failure (as assessed by tumor imaging). LFS data will be collected from the end of SBRT, until the patient experiences recurrence, completes the 5-year follow-up after SBRT, or experiences death from any cause (whichever is sooner). The LFS at 2 years after completion of SBRT will be calculated based on Kaplan-Meier estimates
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- OTHER Quality-of-Life Assessment
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Positron Emission Tomography
- OTHER Radiology, Treatment Planning
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2023-11-20 |
| Est. Completion | 2026-03-01 |
| Phase | NA |
What NCT05802186 shows while recruiting
NCT05802186 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 159-participant average among 47 other Lung Non-Small Cell Carcinoma trials with a reported enrollment target (56% lower).
The record links to 6 conditions, with Lung Non-Small Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.
NCT05802186 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05802186 about?
NCT05802186 is a clinical study titled "Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study". This phase II trial tests the effectiveness and safety of artificial intelligence (AI) to determine dose recommendation during stereotactic body radiation therapy (SBRT) planning in patients with primary lung cancer or tumors that has spread from another primary site to the lung (metastatic). SBRT u...
What is the current status of trial NCT05802186?
This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2023-11-20. Estimated completion is 2026-03-01.
What conditions does trial NCT05802186 study?
This clinical trial studies the following conditions: Lung Non-Small Cell Carcinoma, Lung Carcinoma, Stage IIIA Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage I Lung Cancer AJCC v8.
What interventions are being tested in trial NCT05802186?
The interventions under investigation include: Computed Tomography (PROCEDURE), Quality-of-Life Assessment (OTHER), Magnetic Resonance Imaging (PROCEDURE), Positron Emission Tomography (PROCEDURE), Radiology, Treatment Planning (OTHER).
Who is sponsoring clinical trial NCT05802186?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05802186 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Non-Small Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05802186's enrollment target sits among peer trials
70 20th of 47 higher than 28 of 47 other Lung Non-Small Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Non-Small Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy
RECRUITING · NA
-
Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers
RECRUITING · NA
-
The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer
RECRUITING · NA
-
A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer
RECRUITING · NA
-
Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial
RECRUITING · NA
-
Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI